Vanda Pharmaceuticals Inc (VNDA) announced early Wednesday that its insomnia drug, VEC-162, showed positive results in a phase III clinical trial. The drug met many endpoints, and had a statistically significant difference in inducing and maintaining sleep compared to placebo.
» Search Healthcare-Specific Tags: Vanda Pharmaceuticals - Drug VEC-162 - Insomnia Drug
» Wires


Comments